About this EventAdd to calendar
Please join us for a conversation with Dr. Laird Forrest and Dr. Russell Swerdlow, Co-founders of Aerobyx.
Wednesday, Sept. 8 | 12 - 1 p.m.
Aerobyx was founded by KU faculty members Laird Forrest, Eli Michaelis, and Russell Swerdlow in December, 2017. The focus of the company is to advance the development of compounds designed to enhance brain bioenergetics. Aerobyx therapeutics are intended for the treatment of diseases that feature depressed brain energy metabolism, and especially Alzheimer’s disease. The company, which is administratively based at the BTBC in Lawrence, has so far received an R43 award from the NIA. KUCTC has applied for a permanent composition of matter-based patent that covers novel compounds generated by the company founders.
Dr. Laird Forrest is a professor in the Department of Pharmaceutical Chemistry at the University of Kansas. He received his undergraduate degree in Chemical Engineering at Auburn, and his PhD in Chemical and Biomolecular Engineering from the University of Illinois-Urbana Champaign. Dr. Forrest’s research focuses on prodrug design and drug formulation.
Dr. Russell Swerdlow is a professor in the Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and Molecular Biology at the University of Kansas School of Medicine. He directs the University of Kansas Alzheimer’s Disease Center, its Neurodegenerative Disorders Program, and the Heartland Center for Mitochondrial Medicine. He received undergraduate and MD degrees from New York University, and trained as a neurologist and Alzheimer’s specialist at the University of Virginia. He holds the Gene and Marge Sweeney Chair at the University of Kansas and is a recipient of an S. Weir Mitchell Award from the American Academy of Neurology, a Cotzias Award from the American Parkinson’s Disease Association, and a Chancellor’s Club Research Award from the University of Kansas. He currently sits on the NIA Board of Scientific Counselors. Dr. Swerdlow’s research focuses on brain energy metabolism, its role in Alzheimer’s disease, and its therapeutic manipulation.